Follicular Lymphoma Clinical Trials

A listing of 59 Follicular Lymphoma clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Follicular Lymphoma

13 - 24 of 59

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 59 active clinical trials seeking participants for Follicular Lymphoma research studies. The states with the highest number of trials for Follicular Lymphoma participants are Texas, California, New York and Florida.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Evaluating an Investigational Treatment for Hidradenitis Suppurativa

Recruiting

The main objectives of this Phase 2 study are to evaluate the safety and effectiveness of an investigational medication in adults with moderate to severe hidradenitis suppurativa (HS), a chronic skin condition. Participants will be randomly assigned to receive the investigational treatment or a placebo. Should you express interest, the research site will contact you directly to provide further details and address any questions you may have about study requirements, risks/benefits, and compensation.

Conditions:

All Conditions

Hidradenitis suppurativa (Skin disorder)

Dermatology

Learn More

A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

NCT04224493

Recruiting

The participants of this study would have relapsed/refractory follicular lymphoma. Follicular lymphoma is a type of blood cancer. It is referred to as 'relapsed' when the disease has come back after a period of improvement after that follows a treatment regimen and 'refractory' when treatment no longer works. Stage 1 of this trial will study the safety and the level that adverse effects of each of the study drug combinations can be tolerated (known as tolerability). It is also designed to esta... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/27/2025

Locations: Southern Cancer Center, Mobile, Alabama +191 locations

Southern Cancer Center, Mobile, Alabama

Arizona Oncology Associates - Tuscon-Rusadill Road, Tucson, Arizona

TOI - Clinical Research, Cerritos, California

UCSF Fresno, Clovis, California

UC San Diego Health Sciences, La Jolla, California

UCLA Clinical Research Unit Hematology/Oncology, Santa Monica, California

Rocky Mountain Cancer Centers (RMCC) - Boulder, Boulder, Colorado

St. Mary's Hospital and Regional Medical Center - St. Mary's, Grand Junction, Colorado

SCL Health Lutheran Medical Center, Greeley, Colorado

Cancer Specialists of North Florida, Fleming Island, Florida

Florida Cancer Specialists & Research Institute (FCS) - Fort Myers Cancer Center, Fort Myers, Florida

Mayo Clinic - Cancer Clinical Research Office, Jacksonville, Florida

Mayo Clinic, Jacksonville, Florida

Miami Cancer Institute, Miami, Florida

Florida Cancer Affiliates/Ocala Oncology - Clinic, Ocala, Florida

BRCR Medical Center, INC, Plantation, Florida

Florida Cancer Specialists, Saint Petersburg, Florida

Florida Cancer Specialists - Panhandle, Tallahassee, Florida

H Lee Moffitt Cancer Center and Research Institute I, Tampa, Florida

Florida Cancer Specialists & Research Institute (FCS) - Atlantis, West Palm Beach, Florida

Kaiser Permanente Hawaii Moanalua Medical Center, Honolulu, Hawaii

University of Chicago, Chicago, Illinois

Illinois Cancer Specialists, Niles, Illinois

June E. Nylen Cancer Center, Sioux City, Iowa

The University of Kansas Cancer Center, Overland Park, Kansas

University of Maryland, Baltimore, Maryland

The office of Frederick P. Smith, MD, P.C., Chevy Chase, Maryland

Mass General Cancer Center at Newton-Wellesley, Newton, Massachusetts

University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan

St. Joseph Mercy Hospital, Ypsilanti, Michigan

Mayo Clinic - Rochester, Rochester, Minnesota

Saint Louis University Cancer Center, Saint Louis, Missouri

University Of Nebraska Medical Center, Omaha, Nebraska

Astera Cancer Care, East Brunswick, New Jersey

Astera Cancer Center, East Brunswick, New Jersey

Regional Cancer Care Associates-Freehold, Freehold, New Jersey

Hackensack University Medical John Theurer Cancer Center, Hackensack, New Jersey

Regional Cancer Care Associates LLC - Howell, Howell, New Jersey

Regional Cancer Care Associates LLC - Little Silver, Little Silver, New Jersey

New Mexico Cancer Care Alliance, Albuquerque, New Mexico

New York Oncology Hematology, P.C., Albany, New York

Northwell Health/Monter Cancer Center, Lake Success, New York

Weill Cornell Medicine-New York Presbyterian Hospital, New York, New York

Columbia U - Herbert Irving Comprehensive Cancer Center, New York, New York

Memorial Sloan-Kettering Cancer Center, New York, New York

Hematology Oncology Associates of Rockland, P.C., Nyack, New York

Messino Cancer Center, Asheville, North Carolina

Levine Cancer Institute - Concord, Concord, North Carolina

FirstHealth of the Carolinas, Pinehurst, North Carolina

Gabrail Cancer Center Research, Canton, Ohio

Oncology Hematology Care (OHC), Inc. - Kenwood Office, Cincinnati, Ohio

Willamette Valley Cancer Institute and Research Center - Oncology, Eugene, Oregon

University of Pittsburgh Medical Center - Oncology, Pittsburgh, Pennsylvania

Western Pennsylvania Hospital Hematology & Cellular Therapy, Pittsburgh, Pennsylvania

Tennessee Oncology, PLLC, Chattanooga, Tennessee

University of Tennessee Medical Center - Cancer Institute, Knoxville, Tennessee

Sarah Cannon Research Institute, Nashville, Tennessee

Texas Oncology - Amarillo, Amarillo, Texas

Texas Oncology-Austin Midtown, Austin, Texas

Texas Oncology - Medical City Dallas Pediatric Hematology, Dallas, Texas

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, Texas

The University of Texas MD Anderson Cancer Center, Houston, Texas

Millennium Physicians - Oncology, Houston, Texas

Texas Oncology, Plano, Texas

Mays Cancer Center, San Antonio, Texas

UT Health East Texas HOPE Cancer Center - Tyler, Tyler, Texas

USO Texas Oncology - Tyler, Tyler, Texas

Texas Oncology- Weslaco, Weslaco, Texas

Utah Cancer Specialists/ IHO Corp, Salt Lake City, Utah

Huntsman Cancer Institute; The University of Utah, Salt Lake City, Utah

Peninsula Cancer Institute, Chesapeake, Virginia

Virginia Cancer Specialists, Gainesville, Virginia

Oncology and Hematology Associates of Southwest Virginia Inc., Roanoke, Virginia

MC Rockwood Cancer Bl Specialty Ctr - North, Spokane, Washington

Yakima Valley Memorial Hospital - North Star Lodge Cancer Center, Yakima, Washington

Royal Adelaide Hospital, Adelaide, South Australia

Flinders Medical Centre, Bedford Park, South Australia

Monash Health, Clayton, Victoria

Barwon Health, University Hospital Geelong, Geelong, Victoria

Hollywood Private Hospital, Nedlands, Western Australia

GenesisCare - St Andrew's, Adelaide, Not set

Peninsula Health - Frankston, Frankston, Not set

Gold Coast University Hosptial, Southport, Not set

CHU Dinant Godinne UCL Namur, Yvoir, Namur

Universitair Ziekenhuis Gent, Gent, Oost-Vlaanderen

UZ Leuven - Campus Gasthuisberg, Leuven, Vlaams Brabant

University Health Network Princess Margaret Hospital, Toronto, Ontario

Centre Hospitalier de l'Universite de Montreal (CHUM), Montréal, Quebec

Sir Mortimer B Davis/Jewish General Hospital, Montréal, Quebec

Fujian Medical University Union Hospital, Fuzhou, Fujian

The First Affiliated Hospital of Xiamen University, Xiamen, Fujian

The Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou

The Second Affiliated Hospital Zhejiang University School of Medicine, Zhejiang, Hangzhou

The Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei

Henan Provincial People's Hospital, Zhengzhou, Henan

Henan Cancer Hospital, Zhengzhou, Henan

Hunan Cancer Hospital, Changsha, Hunan

The First Bethune Hospital of Jilin University, Changchun, Jinlin

The Affiliated Hospital of Qingdao University, Qingdao, Shandong

Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai

Shanxi Bethune Hospital, Taiyuan, Shanxi

Peking University Third Hospital, Beijing, Not set

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Not set

Centre Hospitalier Universitaire de Bordeaux-Hopital du Haut Leveque, Pessac Cedex, Aquitaine

CHRU Brest Hôp Morvan, Brest, Bretagne

Institut Bergonie, Bordeaux, Gironde

Centre Hosp Mulh Hop Emile Muller, Mulhouse, Haut-Rhin

Centre Henri Becquerel, Rouen, Haute-Normandie

CHU de Limoges Dupuytren, Limoges, Haute-Vienne

CHU de Grenoble - Hopital Albe, La Tronche, Isere

CHU de Nantes - Hematologie, Nantes, Loire-Atlantique

CHRU de Lille Hop Claude Huriez, Lille, Nord

Centre Hospitalier Le Mans, Le Mans, Sarthe

Centre Hospitalier Universitaire D'Angers - Hématologie Clinique, Angers, Not set

CHRU de Besançon- Hopital Jean Minjoz, Besancon, Not set

CHU Caen, Caen, Not set

CHU de Clermont-Ferrand, site Estaing, Clermont-Ferrand, Not set

Centre Hospitalier Docteur Schaffner, Lens, Not set

L'Hôpital Privé Confluent, Nantes, Not set

L'hôpital Privé du Concluent, Nantes, Not set

Hopital Saint Louis, Paris, Not set

Centre Hospitalier Universitaire de Poitiers, Poitiers, Not set

Centre Hospitalier - Hôpital de jour d'Hématologie, Périgueux, Not set

CHU de Nancy Brabois, Vandœuvre-lès-Nancy, Not set

Centre Hospitalier Bretagne Atlantique, Vannes, Not set

Institut Gustave Roussy, Villejuif, Not set

Hopital Henri Mondor - Hemopathies Lymphoides, Créteil, Île-de-France

Diakoneo Diak Schwaebisch Hall gGmbH, Schwäbisch Hall, Baden-Württemberg

Klinikum Der Universität München AöR, München, Bayern

Klinikum rechts der Isar der Technischen Universitat Muenche, München, Bayern

Universitätsmedizin Mainz, Mainz, Hessen

Universitaetsklinikum Bonn AöR, Bonn, Nordrhein-Westfalen

Kliniken Maria Hilf GmbH, Moenchengladbach, Nordrhein-Westfalen

Städt. Krankenhaus Kiel, Kiel, Schleswig-Holstein

Debreceni Egyetem Klinikai Központ, Debrecen, Hajdú-Bihar

Semmelweis Egyetem Általános Orvostudományi Kar, Budapest, Not set

Országos Onkológiai Intézet, Budapest, Not set

Del-pesti Centrumkorhaz Orszagos Hematologiai és Infektologiai Intezet, Budapest, Not set

AOU Federico II, Napoli, Campania

Istituto Romagnolo per lo Studio dei Tumori (IRST) Dino Amadori IRCCS, Meldola, Forli-Cesena

ASST Spedali Civili di Brescia, Brescia, Not set

PO Garibaldi-Nesima, ARNAS Garibaldi, Catania, Not set

AOU Careggi, Firenze, Not set

Ospedale Vito Fazzi, ASL Lecce, Lecce, Not set

IEO - Istituto Europeo di Oncologia, IRCCS, Milano, Not set

Ospedale Maggiore Policlinico, Fondazione IRCCS Ca' Granda, Milano, Not set

Ospedale San Gerardo, ASST di Monza, Monza, Not set

Ospedale Civile S.Spirito, PO di Pescara, AUSL Pescara, Pescara, Not set

Ospedale Infermi di Rimini, AUSL Rimini, Distretto di Rimini, Presidio di Rimini, Santarcangelo di Romagna e Novafeltria, Rimini, Not set

Catholic University Of Sacred Heart, Roma, Not set

PU Campus Bio-Medico di Roma, Roma, Not set

Regina Elena, Istituto Nazionale dei Tumori , IFO, IRCCS, Roma, Not set

Azienda Ospedaliera Santa Maria di Terni, Terni, Not set

Azienda Ospedaliera Ordine Mauriziano di Torino, Ospedale Umberto I di Torino, Torino, Not set

Azienda Sanitaria Universitaria Giuliano Isontina (ASU GI), Ospedale Maggiore, Trieste, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp]

Severance Hospital, Yonsei University Health System, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Samsung Medical Center, Seoul, Seoul Teugbyeolsi [Seoul-T'ukp

Seoul National University Hospital, Seoul, Seoul Teugbyeolsi

Pusan National University Hospital, Busan, Not set

Gachon University Gil Medical Center, Incheon, Not set

Ajou University Hospital, Suwon, Not set

Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie - Państwowy Instytut Badawczy, Warszawa, Mazowieckie

Centrum Medyczne Pratia Poznan, Skorzewo, Wielkopolskie

Pratia Onkologia Katowice, Katowice, Not set

Pratia MCM Krakow, Kraków, Not set

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka w Slupsku Sp. z o.o., Słupsk, Not set

MICS Centrum Medyczne Torun, Torun, Not set

MTZ Clinical Research powered by Pratia, Warszawa, Not set

Uniwersytecki Szpital Kliniczny im. J. Mikulicza-Radeckiego we Wroclawiu, Wroclaw, Not set

Hospital Universitari Vall d'Hebrón, Barcelona, Cataluny

Hospital Costa del Sol, Marbella, Málaga

Hospital Del Mar, Barcelona, Not set

Hospital Univ. Infanta Leonor, Madrid, Not set

Hospital Universitario La Paz, Madrid, Not set

Hospital Universitario de Salamanca, Salamanca, Not set

Hospital Universitario Nuestra Señora de Valme, Sevilla, Not set

Buddihist Tzu Chi Medical Foundation- Hualien Tzu Chi Hospital, Hualien City, Not set

Chang Gung Medical Foundation - Kaohsiung Chang Gung Memorial Hospital - Hemato-Oncology, Kaohsiung, Not set

Taichung Veterans General Hospital, Taichung, Not set

National Cheng Kung University Hospital, Tainan, Not set

National Taiwan University Hospital, Taipei, Not set

Ankara University Medical Faculty - Hematology, Ankara, Not set

Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research, Ankara, Not set

Gazi University Medical Faculty, Ankara, Not set

Ondokuz Mayis University Medical Faculty - Hematology, Samsun, Not set

Western General Hospital - Haematology, Edinburgh, Edinburgh, City Of

Imperial College Healthcare NHS Trust - Hammersmith Hospital, London, London City

St Bartholomew's Hospital Barts Health NHS Trust, London, London, City Of

Royal Cornwall Hospitals NHS Trust - Royal Cornwall Hospital, Cornwell, Not set

Beatson West of Scotland Cancer Centre, Glasgow, Not set

Northwick Park Hospital Middlesex, United Kindgom, HA1 3UJ, Middlesex, Not set

Conditions: Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma

Learn More ›

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

NCT06794268

Recruiting

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/21/2025

Locations: CIBMTR, Milwaukee, Wisconsin

Conditions: Follicular Lymphoma

Learn More ›

A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL)

NCT05512390

Recruiting

B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections). Follicular Lymphoma is a slow-growing type of non-Hodgkin lymphoma. Chronic lymphocytic leukemia (CLL) is the most common leukemia (cancer of blood cells). The purpose of this study is to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of ABBV-319 in adult participants in relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL)... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/19/2025

Locations: University of Arizona Cancer Center - Tucson /ID# 247752, Tucson, Arizona +13 locations

Conditions: Diffuse Large B-Cell Lymphoma, Chronic Lymphocytic Leukemia, Follicular Lymphoma

Learn More ›

A Study of Zilovertamab Vedotin (MK-2140) as Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies (MK-2140-006)

NCT05458297

Recruiting

The purpose of this study is to assess the safety and tolerability of zilovertamab vedotin as monotherapy and in combination in participants with select B-cell lymphomas including mantle cell lymphoma (MCL), Richter's transformation lymphoma (RTL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL). This study will also evaluate zilovertamab vedotin as monotherapy and in combination with respect to objective response rate. * Cohort A: Participants with relapsed or refractory MCL r... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/18/2025

Locations: Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska +107 locations

Alaska Oncology and Hematology ( Site 0037), Anchorage, Alaska

Banner MD Anderson Cancer Center ( Site 0040), Gilbert, Arizona

Banner MD Anderson Cancer Center - University Medical Center Phoenix-Medical Oncology ( Site 0036), Phoenix, Arizona

University of Colorado Anschutz Medical Campus-The Center for Cancer and Blood Disorders ( Site 0008, Aurora, Colorado

Cancer Care Specialists of Illinois ( Site 0031), Decatur, Illinois

University of Kansas Medical Center-Division of Hematologic Malignancies and Cellular Therapeutics (, Fairway, Kansas

Norton Women's and Children's Hospital-Norton Cancer Institute - St. Matthews ( Site 0007), Saint Matthews, Kentucky

Greenebaum Comprehensive Cancer Center-Hematology & Multiple Myeloma ( Site 0010), Baltimore, Maryland

Tufts Medical Center ( Site 0024), Boston, Massachusetts

Massachusetts General Hospital ( Site 0018), Boston, Massachusetts

Dana-Farber Cancer Institute-Lymphoma ( Site 0026), Boston, Massachusetts

University of Michigan ( Site 0009), Ann Arbor, Michigan

Henry Ford Hospital ( Site 0035), Detroit, Michigan

Icahn School of Medicine at Mount Sinai ( Site 0023), New York, New York

Sanford Fargo Medical Center-Roger Maris Cancer Center ( Site 0014), Fargo, North Dakota

The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C, Columbus, Ohio

Avera Cancer Institute- Research ( Site 0011), Sioux Falls, South Dakota

Medical Oncology Associates, PS ( Site 0005), Spokane, Washington

University of Wisconsin Hospitals and Clinics-Carbone Cancer Center ( Site 0030), Madison, Wisconsin

MEDICAL COLLEGE OF WISCONSIN ( Site 0021), Milwaukee, Wisconsin

Liga Norte Riograndense Contra o Câncer-Centro de Pesquisa Clínica ( Site 1807), Natal, Rio Grande Do Norte

Instituto Nacional de Câncer - INCA-Divisão de Pesquisa Clínica e Desenvolvimento Tecnológico HC1 (, Rio de Janeiro, Not set

ICESP - INSTITUTO DO CÂNCER DO ESTADO DE SÃO PAULO ( Site 1808), Sao Paulo, Not set

Hospital Paulistano-Americas Oncologia ( Site 1805), Sao Paulo, Not set

BC Cancer Vancouver-Clinical Trials Unit ( Site 0201), Vancouver, British Columbia

The Moncton Hospital-Oncology ( Site 0211), Moncton, New Brunswick

QEII Health Sciences Centre - Victoria General Site ( Site 0213), Halifax, Nova Scotia

Lawson Health Research Institute - London Health Sciences Ce-London Regional Cancer Program ( Site 0, London, Ontario

Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0200), Toronto, Ontario

Jewish General Hospital ( Site 0202), Montreal, Quebec

Allan Blair Cancer Centre-Care Services ( Site 0208), Regina, Saskatchewan

IC La Serena Research ( Site 1909), La Serena., Coquimbo

Centro de Estudios Clínicos SAGA-CECSAGA ( Site 1907), Santiago, Region M. De Santiago

Clínica Inmunocel ( Site 1910), Santiago, Region M. De Santiago

Clínica Alemana de Santiago ( Site 1903), Santiago, Region M. De Santiago

Beijing Cancer hospital ( Site 1200), Beijing, Beijing

Zhujiang Hospital ( Site 1207), Guangzhou, Guangdong

Southern Medical University Nanfang Hospital ( Site 1202), Guangzhou, Guangdong

Sun Yat-sen University Cancer Center ( Site 1201), Guangzhou, Guangdong

Henan Cancer Hospital-hematology department ( Site 1212), Zhengzhou, Henan

Union Hospital Tongji Medical College Huazhong University of Science and Technology ( Site 1210), Wuhan, Hubei

Tongji Hospital Tongji Medical,Science & Technology ( Site 1221), Wuhan, Hubei

The First Affiliated Hospital of Soochow University-hematology department ( Site 1218), Suzhou, Jiangsu

The Affiliated Hospital of Xuzhou Medical College ( Site 1223), Xuzhou, Jiangsu

The First Affiliated Hospital of Nanchang University ( Site 1204), Nanchang, Jiangxi

Jiangxi Provincial Cancer Hospital ( Site 1213), Nanchang, Jiangxi

Jilin Province Tumor Hospital-oncology department ( Site 1220), Chuangchun, Jilin

Fudan University Shanghai Cancer Center ( Site 1208), Shanghai, Shanghai

West China Hospital of Sichuan University-Head and Neck Oncology ( Site 1206), Cheng Du, Sichuan

The First Affiliated Hospital, Zhejiang University ( Site 1211), Hangzhou, Zhejiang

Zhejiang Cancer Hospital ( Site 1214), Hangzhou, Zhejiang

Fakultní nemocnice Brno Bohunice-Interni hematologicka a onkologicka klinika ( Site 0300), Brno, Brno-mesto

Fakultni nemocnice Ostrava-Klinika Hematoonkologie ( Site 0301), Ostrava, Moravskoslezsky Kraj

Vseobecna fakultni nemocnice v Praze-I. Interní klinika - klinika hematologie ( Site 0302), Praha 2, Not set

North Estonia Medical Centre Foundation ( Site 0401), Tallinn, Harjumaa

Universitaetsklinikum Ulm ( Site 0502), Ulm, Baden-Wurttemberg

Universitaetsklinikum Koeln ( Site 0506), Köln, Nordrhein-Westfalen

St. James's Hospital ( Site 0600), Dublin, Not set

Emek Medical Center-Hematology Unit ( Site 0705), Afula, Not set

Soroka Medical Center-Hematology Department ( Site 0707), Be'er Sheva, Not set

Rambam Health Care Campus-Hematology and Bone Marrow Transplantation ( Site 0706), Haifa, Not set

Carmel Hospital ( Site 0709), Haifa, Not set

Hadassah Medical Center ( Site 0701), Jerusalem, Not set

Galilee Medical Center ( Site 0710), Nahariya, Not set

Sheba Medical Center-Hemato Oncology ( Site 0700), Ramat Gan, Not set

IRCCS - AOU di Bologna-SSD: Diagnosi e terapie dei linfomi e delle sindromi linfoproliferative cron, Bologna, Emilia-Romagna

Humanitas-U.O di Oncologia medica ed Ematologia ( Site 0802), Rozzano, Milano

Azienda Ospedaliera Nazionale SS. Antonio e Biagio e Cesare -Azienda Ospedaliera Nazionale SS. Ant, Alessandria, Not set

Fondazione Policlinico Universitario Agostino Gemelli IRCCS -ISTITUTO DI EMATOLOGIA ( Site 0804), Roma, Not set

National Hospital Organization Nagoya Medical Center ( Site 1108), Nagoya, Aichi

Hokkaido University Hospital ( Site 1104), Sapporo, Hokkaido

Tokai University Hospital ( Site 1100), Isehara, Kanagawa

Tohoku University Hospital ( Site 1106), Sendai-shi, Miyagi

Kindai University Hospital ( Site 1102), Sayama, Osaka

National Cancer Center Hospital ( Site 1103), Chuo-ku, Tokyo

The Cancer Institute Hospital of JFCR ( Site 1101), Koto, Tokyo

Kyushu University Hospital ( Site 1105), Fukuoka, Not set

Okayama University Hospital ( Site 1107), Okayama, Not set

Seoul National University Hospital ( Site 1300), Seoul, Not set

Samsung Medical Center ( Site 1301), Seoul, Not set

Centro Medico Monte Carmelo ( Site 1702), Arequipa, Ariqipa

INSTITUTO NACIONAL DE ENFERMEDADES NEOPLASICAS ( Site 1700), Lima, Not set

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumat-Oddiał Hematologii Ogólnej ( Site 1008), Łódź, Lodzkie

Centrum Onkologii Ziemi Lubelskiej-Oddzial Hematologiczny ( Site 1006), Lublin, Lubelskie

Pratia MCM Krakow ( Site 1001), Krakow, Malopolskie

Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( S, Warszawa, Mazowieckie

Samodzielny Publiczny Zakład Opieki Zdrowotnej MSWiA w Olsztynie-Oddzial Kliniczny Hematologii ( Sit, Olsztyn, Warminsko-mazurskie

Champalimaud Foundation ( Site 2002), Lisbon, Lisboa

Unidade Local de Saude de Braga - Hospital de Braga ( Site 2001), Braga, Not set

Instituto Português de Oncologia do Porto Francisco Gentil, EPE ( Site 2000), Porto, Not set

National Cancer Centre Singapore ( Site 1500), Singapore, Central Singapore

Instituto Catalan de Oncologia - Hospital Duran i Reynals-Haematology Department ( Site 4003), L'Hospitalet Del Llobregat, Barcelona

Hospital Universitari Vall d'Hebron ( Site 4004), Barcelona, Cataluna

MD Anderson Cancer Center ( Site 4006), Madrid, Madrid, Comunidad De

Clinica Universidad de Navarra ( Site 4005), Pamplona, Navarra

Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca-Hematology ( S, Salamanca, Not set

Skånes Universitetssjukhus Lund ( Site 5000), Lund, Skane Lan

Akademiska sjukhuset-Blod- och tumörsjukdomar ( Site 5002), Uppsala, Uppsala Lan

Sahlgrenska Universitetssjukhuset ( Site 5003), Gothenburg, Vastra Gotalands Lan

Mega Medipol-Hematology ( Site 6009), Stanbul, Istanbul

Ankara Universitesi Tip Fakultesi Hastanesi-hematology ( Site 6001), Ankara, Not set

Trakya University ( Site 6005), Edirne, Not set

Ege Universitesi Hastanesi ( Site 6002), İzmir, Not set

Ondokuz Mayıs Universitesi-Oncology department ( Site 6004), Samsun, Not set

The Royal Cornwall Hospital-Haematology ( Site 7006), Truro, Cornwall

University College London Hospital ( Site 7001), London, London, City Of

The Churchill Hospital ( Site 7002), Oxford, Oxfordshire

The Christie NHS Foundation Trust ( Site 7007), Manchester, Not set

Conditions: Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma, Richter Transformation Lymphoma

Learn More ›

CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies

NCT04186520

Recruiting

This is a Phase I/II, interventional, single-arm, open-label, treatment study designed to evaluate the safety and efficacy of Interleukin-7 and Interleukin-15 (IL-7/IL-15) manufactured chimeric antigen receptor (CAR)-20/19-T cells as well as the feasibility of a flexible manufacturing schema in adult patients with B cell malignancies that have failed prior therapies.

Gender:

ALL

Ages:

Between 18 years and 80 years

Trial Updated:

02/17/2025

Locations: Medical College of Wisconsin and Froedtert Hospital, Milwaukee, Wisconsin

Conditions: Non Hodgkin Lymphoma (NHL), Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Central Nervous System Lymphoma

Learn More ›

LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies

NCT05990465

Recruiting

This is a phase I, interventional, single arm, open label, treatment study designed to evaluate the safety and efficacy of LV20.19 CAR -T cells with pirtobrutinib bridging and maintenance in adult patients with B cell malignancies that have failed prior therapies.

Gender:

ALL

Ages:

Between 18 years and 81 years

Trial Updated:

02/17/2025

Locations: Froedtert & the Medical College of Wisconsin, Milwaukee, Wisconsin

Conditions: Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma, Burkitt Lymphoma

Learn More ›

Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma

NCT04545762

Recruiting

This study will assess safety and feasibility of infusing genetically modified autologous T cells transduced to express a chimeric antigen receptor targeting the B cell surface antigen Cluster of Differentiation 19 (CD19)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/05/2025

Locations: University of California, San Francisco, San Francisco, California

Conditions: Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Diffuse Large B Cell Lymphoma, Small Lymphocytic Lymphoma, Transformed Lymphoma

Learn More ›

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

NCT03314974

Recruiting

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

Gender:

ALL

Ages:

60 years and below

Trial Updated:

02/03/2025

Locations: Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota

Conditions: Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Lymphoma, Chronic Myelogenous Leukemia, Plasma Cell Leukemia, Myeloproliferative Neoplasms, Myelofibrosis, Myelodysplasia, Refractory Anemia, High Risk Anemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Diffuse Large Cell Non Hodgkins Lymphoma, Lymphoblastic Lymphoma, Burkitt Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult, Multiple Myeloma, Juvenile Myelomonocytic Leukemia, Biphenotypic/Undifferentiated/Prolymphocytic Leukemias, MRD Positive Leukemia, Natural Killer Cell Malignancies, Acquired Bone Marrow Failure Syndromes

Learn More ›

Evaluation of Human Immune Responses Vaccination in Patients with Lymphoma

NCT03501576

Recruiting

This clinical trial evaluates the influenza virus vaccination in evaluating human immune response in patients with lymphoma. Evaluating immune response may increase the understanding of how the immune system changes when patients receive treatment for lymphomas by looking at the antibody levels and the level of the different cells that make up the immune system over time compared to those without lymphoma.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Emory University Hospital Midtown, Atlanta, Georgia +1 locations

Conditions: Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma

Learn More ›

Epcoritamab, Zanubrutinib, and Rituximab (EZR) for R/R FL Relapsed or Refractory Follicular Lymphoma

NCT06563596

Recruiting

The purpose of this study is to determine how effective and safe the combination of epcoritamab, zanubrutinib, and rituximab is in treating participants with relapse or refractory Follicular Lymphoma (FL). * The names of the study drugs involved in this research study are: * Epcoritamab (a type of antibody) * Zanubrutinib (a type of Bruton tyrosine kinase inhibitor) * Rituximab (a type of monoclonal antibody)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/23/2025

Locations: Brigham and Women's Hospital, Boston, Massachusetts +1 locations

Conditions: Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma

Learn More ›

Rituximab and Zanubrutinib in Patients With Indolent B-cell Lymphomas

NCT06350318

Recruiting

The purpose of the study is to establish the safety and efficacy of zanubrutinib in combination with rituximab for people with untreated B-cell lymphomas (marginal zone lymphoma and follicular lymphomas).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/22/2025

Locations: Moffitt Cancer Center, Tampa, Florida

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, B-Cell Lymphoma

Learn More ›

Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma

NCT05783596

Recruiting

The purpose of this study is to determine how effective and safe the combination of glofitamab and obinutuzumab is in treating patients with Follicular Lymphoma (FL) and Marginal Zone Lymphoma (MZL) who have not received other treatments for their lymphoma. The names of the study drugs involved in this study are: * Glofitamab (a type of immunotherapy) * Obinutuzumab (a type of immunotherapy)

Gender:

ALL

Ages:

18 years and above

Trial Updated:

01/12/2025

Locations: Beth Israel Deaconess Medical Center, Boston, Massachusetts +3 locations

Conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-hodgkin Lymphoma

Learn More ›

13 - 24 of 59